Clene Inc. (CLNN) Stock Price & Analysis
Clene Inc. (CLNN) fell 1.17% to USD 5.51 as of June 10, 2026 at 15:44 UTC, according to Nexqual real-time market data.
CLNN last closed at USD 5.57; the session ranged USD 5.4–5.69 on volume of 15,332 shares. Market capitalization is $70.34M, with a 52-week range of USD 3.25–13.5 (NCM). Source: Nexqual, June 10, 2026 at 15:44 UTC.
Key Statistics (as of June 10, 2026 at 15:44 UTC)
| Price | USD 5.51 |
|---|---|
| Change | ▼ 1.17% (down) |
| Previous Close | USD 5.57 |
| Open | USD 5.54 |
| Day Range | USD 5.4 – 5.69 |
| 52-Week Range | USD 3.25 – 13.5 |
| Volume | 15,332 shares |
| Market Cap | $70.34M |
| Exchange | NCM |
Technical Analysis (CLNN)
Nexqual's technical model rates CLNN "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of June 10, 2026 at 15:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.04 (neutral) |
| vs SMA50 | Below (USD 6.3) |
| MACD | -0.26 (negative) |
Analyst Ratings (CLNN)
Wall Street analysts rate CLNN "Strong Buy" based on 5 analysts, with a mean price target of USD 32.2 (range USD 20–50), per Nexqual as of June 10, 2026 at 15:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 32.2 |
| High Target | USD 50 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (CLNN)
| EPS Estimate | USD -0.26 |
|---|---|
| Revenue Estimate | $48,800 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.24 vs est -0.71 ▲ beat |
| 2025-12-31 | USD -0.78 vs est -0.42 ▼ miss |
| 2025-09-30 | USD -0.61 vs est -0.56 ▼ miss |
| 2025-06-30 | USD -0.88 vs est -0.46 ▼ miss |
Source: Nexqual, June 10, 2026 at 15:44 UTC.
Financials & Fundamentals (CLNN)
| Total Revenue | $134,000 |
|---|---|
| Revenue Growth (YoY) | -81.50% |
| Gross Margin | +82.84% |
| Operating Margin | -13740.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.94 |
| Total Cash | $5.94M |
| Total Debt | $22.05M |
| Free Cash Flow | $-11.58M |
Source: Nexqual, June 10, 2026 at 15:44 UTC.
Financial Health Score (CLNN)
Nexqual rates Clene Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 15:44 UTC.
| Growth | Critical — Revenue -42% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $6M cash vs $22M debt |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Mixed — No data |
Ownership (CLNN)
| Insider Ownership | +17.06% |
|---|---|
| Institutional Ownership | +20.44% |
| Shares Outstanding | 12.78M |
| Float | 10.50M |
| Short % of Float | +11.78% |
Source: Nexqual, June 10, 2026 at 15:44 UTC.
Leadership (CLNN)
Clene Inc. is led by Robert Etherington (age 58), CEO, President & Director, per Nexqual as of June 10, 2026 at 15:44 UTC.
| CEO, President & Director | Robert Etherington (age 58) |
|---|---|
| Chief Financial Officer | Morgan R. Brown (age 57) |
Major Backers & Investors (CLNN)
Notable institutional backers of Clene Inc. include Boxer Capital Management, LLC, SymBiosis Capital Partners, LLC, Scoggin Management, LP, according to Nexqual as of June 10, 2026 at 15:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Boxer Capital Management, LLC | 3.74% |
| SymBiosis Capital Partners, LLC | 3.37% |
| Scoggin Management, LP | 2.35% |
| Ensign Peak Advisors, Inc | 2.02% |
| Fidelity | 0.63% |
| Lunt Capital Management, Inc. | 0.41% |
| Peak6 LLC | 0.39% |
| Parsons Capital Management Inc/RI | 0.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.16% |
| Geode Capital | 0.75% |
Source: Nexqual, June 10, 2026 at 15:44 UTC.
From Clene Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- These include:       Our CSN  Therapeutics Platform   By uniting concepts from electrochemistry, nanotechnology, plasma and quantum physics, materials science, and biochemistry, we have created and refined a proprietary electrocrystallization method that results in single component or multiple component nanocrystals of the transition elements that are clean-surfaced, highly faceted, and biologically catalytically active (see Figure 1 for example nanocrystals).
- The HEALEY ALS Platform Trial is the first platform trial for ALS and is intended to accelerate the development of ALS therapies by simultaneously testing multiple therapeutics under a master protocol, in order to reduce costs, decrease trial time, and increase patient participation.
- The new analysis incorporated up to 42 months (3.5 years) of survival follow-up and 76 weeks of long-term NfL biomarker results, including an NfL responder subset (the "CNM-Au8 NfL Responders") from the HEALEY ALS Platform Trial who had consistent and sustained NfL reductions, comprising nearly half of all CNM-Au8 patients.
- To our knowledge, we believe we are the only company currently developing catalytically-active nanocrystals to directly modulate biological systems as therapeutic drug candidates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DRMA | Dermata Therapeutics, Inc. | USD 1.22 | ▲ 0.83% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▼ 1.98% |
| EVAX | Evaxion A/S | USD 3.81 | ▲ 2.14% |
| UNCY | Unicycive Therapeutics, Inc. | USD 7.77 | ▲ 16.59% |
| INAB | IN8bio, Inc. | USD 1.46 | ▲ 1.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 15:44 UTC. This page is informational and not investment advice.